BeOne Medicines (NASDAQ:ONC) SVP Sells $337,932.36 in Stock

by · The Cerbat Gem

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) SVP Chan Henry Lee sold 1,044 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $323.69, for a total transaction of $337,932.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

  • On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44.
  • On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The stock was sold at an average price of $265.98, for a total transaction of $156,928.20.
  • On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total value of $110,265.64.
  • On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.
  • On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total value of $103,159.04.

BeOne Medicines Stock Down 0.7%

Shares of BeOne Medicines stock traded down $2.24 on Monday, reaching $313.77. The company’s stock had a trading volume of 359,505 shares, compared to its average volume of 278,683. The company has a market capitalization of $34.43 billion, a price-to-earnings ratio of 70.19 and a beta of 0.49. The firm’s fifty day simple moving average is $293.50 and its two-hundred day simple moving average is $309.18. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $253.95 and a 52 week high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. boosted their target price on BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Wells Fargo & Company started coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 price target for the company. Truist Financial boosted their price objective on shares of BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Finally, Guggenheim increased their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $394.00.

View Our Latest Research Report on BeOne Medicines

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Generali Investments Management Co LLC bought a new stake in BeOne Medicines during the 2nd quarter worth approximately $2,280,000. Charles Schwab Trust Co bought a new position in shares of BeOne Medicines in the second quarter worth approximately $855,000. Steadtrust LLC boosted its position in shares of BeOne Medicines by 3.7% in the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock worth $399,000 after purchasing an additional 50 shares during the period. Empowered Funds LLC purchased a new stake in shares of BeOne Medicines in the first quarter worth $201,000. Finally, Bank of America Corp DE increased its stake in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after purchasing an additional 26,441 shares in the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

See Also